80980-89-8

Usage

Uses

Used in Medicinal Chemistry and Drug Development:
4-(4'-Bromophenyl)piperidine is used as a building block in the synthesis of various pharmaceuticals and other organic compounds. Its potential pharmacological activities have been studied, making it a valuable component in the development of new drugs.
Used in Chemical Industry:
The presence of the bromine atom in the molecule of 4-(4'-Bromophenyl)piperidine makes it useful for specific applications in the chemical industry, where its unique properties can be leveraged for various chemical processes and reactions.

InChI:InChI=1/C11H14BrN/c12-11-3-1-9(2-4-11)10-5-7-13-8-6-10/h1-4,10,13H,5-8H2

Upstream product

• 188863-87-8 1-benzyl-4-(4-bromo-phenyl)-1,2,3,6-tetrahydro-pyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 16332-18-6 1-benzyl-4-(4-bromo-phenyl)-piperidin-4-ol 
• 769944-78-7 tert-butyl 4-(4-bromophenyl)piperidine-1-carboxylate 
• 91347-99-8 4-(4-bromo-phenyl)-1,2,3,6-tetrahydro-pyridine 
• 57988-58-6 4-(4-bromophenyl)-4-hydroxy-piperidine 
• 771-99-3 4-phenylpiperidine 
• 18620-02-5 (4-bromophenyl)magnesium bromide 

Downstream Products

• 769944-78-7 tert-butyl 4-(4-bromophenyl)piperidine-1-carboxylate 
• 1160271-32-8 ethyl 4-(4-(piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate 
• 1467059-15-9 5-(4-(1-acetylpiperidin-4-yl)phenyl)-6-chloro-1H-indazole-3-carboxylic acid 
• 1467061-07-9 methyl 5-[4-(1-acetylpiperidin-4-yl)phenyl]-6-chloro-1H-indole-3-carboxylate 
• 1467058-63-4 5-[4-(1-acetylpiperidin-4-yl)phenyl]-6-chloro-1H-indole-3-carboxylic acid 
• 176636-91-2 1-[4-(4-bromophenyl)piperidin-1-yl]ethanone 
• 1428329-80-9 1-(methylsulfonyl)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine 
• 622386-94-1 4-(4-bromophenyl)-1-(methylsulfonyl)piperidine 
• 1187928-85-3 4-(4-bromo-phenyl)-1-methyl-piperidine 

Relevant academic research and scientific papers

Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3

Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple drugs approved or entering late stage clinical trials. A limitation of current inhibitors is vulnerability to gatekeeper resistance mutations. Using a combination of targeted high-throughput screening and structure-based drug design, we have developed a series of aminopyrazole based FGFR inhibitors that covalently target a cysteine residue on the P-loop of the kinase. The inhibitors show excellent activity against the wild-type and gatekeeper mutant versions of the enzymes. Further optimization using SAR analysis and structure-based drug design led to analogues with improved potency and drug metabolism and pharmacokinetics properties.

TRIAZOLE DERIVATIVES AS P2Y14 RECEPTOR ANTAGONISTS

Described are compounds, which are antagonists of the P2Y14 receptor, for example, a compound of formula (I) in which ring A, R1,R2, R3, and n are as described herein. Also provided are dendron conjugates comprising the compounds, and methods of using the compounds, including a method of treating a disorder, such as inflammation, diabetes, insulin resistance, hyperglycemia, a lipid disorder, obesity, a condition associated with metabolic syndrome, and asthma, and a method of antagonizing P214 receptor activity in a cell.

Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists

UDP and UDP-glucose activate the P2Y14 receptor (P2Y14R) to modulate processes related to inflammation, diabetes, and asthma. A computational pipeline suggested alternatives to naphthalene of a previously reported P2Y14R antagonist (3, PPTN) using docking and molecular dynamics simulations on a hP2Y14R homology model based on P2Y12R structures. By reevaluating the binding of 3 to P2Y14R computationally, two alternatives, i.e., alkynyl and triazolyl derivatives, were identified. Improved synthesis of fluorescent antagonist 4 enabled affinity quantification (IC50s, nM) using flow cytometry of P2Y14R-expressing CHO cells. p-F3C-phenyl-triazole 65 (32) was more potent than a corresponding alkyne 11. Thus, additional triazolyl derivatives were prepared, as guided by docking simulations, with nonpolar aryl substituents favored. Although triazoles were less potent than 3 (6), simpler synthesis facilitated further structural optimization. Additionally, relative P2Y14R affinities agreed with predicted binding of alkynyl and triazole analogues. These triazoles, designed through a structure-based approach, can be assessed in disease models.

Structural changes of benzylether derivatives of vesamicol and their influence on the binding selectivity to the vesicular acetylcholine transporter

18F labelled vesamicol analogues, which bind to the vesicular acetylcholine transporter (VAChT) in central cholinergic nerve terminals, are expected to be potential radioligands for the visualisation of cholinergic transmission deficits via pos

3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity

The present invention is directed to pyrrolidine compounds of the formula I: (wherein R1, R2, R3, R4c, R4d, and R4fare defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

Piperidine derivatives

STR1 The invention provides piperidine derivatives of general formula (I) or an acid-addition salt thereof, in which R represents an optionally substituted alkyl, cycloalkyl, aryl or heterocyclyl group: R1 represents an optionally substituted alkyl, alkenyl, akynyl, cycloalkyl, aryl or heterocyclyl group; m represents an integer from 0 to 3; and each of R2 and R3 is independently selected from a group consisting of hydrogen atoms, alkyl and phenyl groups; with the proviso that R does not represent a 4-tert-butylphenyl group; processes for their preparation; compositions containing such compounds and their use as fungicides.